Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

The Effect of Pretreatment With Roc on Succinylcholine Myalgias

NCT04581395 · View on ClinicalTrials.gov ↗

Study Summary

Succinylcholine is a medication (depolarizing muscle relaxant) that is used as part of an anesthetic (going to sleep for surgery). This medication can cause significant muscle soreness. Rocuronium is a medication (non-depolarizing muscle relaxant) that some anesthesia providers believe may reduce muscle soreness caused by succinylcholine if given prior, but this has been controversial. Some anesthesiologists pretreat patients with rocuronium before giving patients succinylcholine, and some do not. The purpose of this study is to examine the effect of pretreatment with rocuronium on muscle soreness associated with succinylcholine administration.

Conditions Studied

Interventions

  • OTHER non-pretreated Succinylcholine
  • DRUG succinylcholine 1 minute after rocuronium pretreatment
  • DRUG succinylcholine 2 minutes following rocuronium pretreatment

Study Locations (1)

Indiana

  • indiana University — Indianapolis

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2020-10-02
Est. Completion 2023-04-25
Phase Phase 3

Sponsor

Indiana University

1,026 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04581395

The ClinicalTrials.gov registry entry for NCT04581395 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 1,026 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myalgia appearing as the primary indexed condition, and to 3 interventions — of which non-pretreated Succinylcholine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04581395 reports 1 study location spanning 1 distinct geographic area — top geographies include Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04581395 about?

NCT04581395 is a clinical study titled "The Effect of Pretreatment With Roc on Succinylcholine Myalgias". Succinylcholine is a medication (depolarizing muscle relaxant) that is used as part of an anesthetic (going to sleep for surgery). This medication can cause significant muscle soreness. Rocuronium is a medication (non-depolarizing muscle relaxant) that some anesthesia providers believe may reduce mu...

What is the current status of trial NCT04581395?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2020-10-02. Estimated completion is 2023-04-25.

What conditions does trial NCT04581395 study?

This clinical trial studies the following conditions: Myalgia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04581395?

The interventions under investigation include: non-pretreated Succinylcholine (OTHER), succinylcholine 1 minute after rocuronium pretreatment (DRUG), succinylcholine 2 minutes following rocuronium pretreatment (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04581395?

This trial is sponsored by Indiana University, which has 1,026 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04581395 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial